T细胞克隆谱在再生障碍性贫血免疫抑制治疗疗效预测中的研究进展  

Advances in the study of T cell cloning in the prediction of immunosuppressive therapy for aplastic anemia

作　　者：董杰[1] 靳玉凤[1] 贾燕[1] DONG Jie;JIN Yu-feng;JIA Yan(The 12th People′s Hospital of Guangzhou City,Guangzhou,Guangdong 510000,China)

机构地区：[1]广州市第十二人民医院,广东广州510000

出　　处：《热带医学杂志》2020年第7期993-996,共4页Journal of Tropical Medicine

基　　金：广州市医药卫生科技项目(2017A011271)。

摘　　要：研究表明,T细胞受体Vβ家族基因(TCR Vβ基因)克隆表达特征、功能及治疗后变化规律,可能决定再生障碍性贫血的临床免疫抑制疗效与预后。本综述旨在介绍T细胞克隆变化规律在抗人胸腺细胞球蛋白(ATG)和环孢素A(CsA)治疗重型再生障碍性贫血患者临床研究中的应用,有助于指导临床对相关治疗的个体化用药,为免疫抑制剂减量和停用时机提供客观的理论依据。Experimental studies have shown that clonal expression characteristics,function and post-treatment changes of T cell receptor Vβfamily gene(TCR Vβgene)may determine the clinical immunosuppressive effect and prognosis of aplastic anemia.This review aims to introduce the application of T cell clonal changes in the clinical study of anti-thymocyteglobulin(ATG)combined with cyclosporin A(CsA)in the treatment of severe aplastic anemia(SAA)patients.It is helpful to guide the clinical individualized medication of related treatment and provide objective theoretical basis for the reduction of immunosuppressant dose and the time of discontinuation.

关 键 词：再生障碍性贫血 致病性T细胞克隆 免疫抑制治疗 

分 类 号：R556.5[医药卫生—血液循环系统疾病]